
Annual report 2025
added 02-25-2026
MiMedx Group Financial Statements 2011-2026 | MDXG
Annual Financial Statements MiMedx Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
779 M | 1.18 B | 954 M | 542 M | 547 M | 1.06 B | 791 M | 276 M | 2.06 B | - | - | - | - | 354 M | 81.2 M |
Shares |
148 M | 147 M | 116 M | 113 M | 110 M | 108 M | 107 M | 106 M | 116 M | - | - | - | - | 81.6 M | 72.5 M |
Historical Prices |
5.27 | 8 | 8.19 | 4.8 | 4.96 | 9.82 | 7.38 | 2.64 | 16.8 | 8.08 | 8.32 | 8.15 | 7.84 | 4.35 | 1.15 |
Net Income |
48.6 M | 42.4 M | 58.2 M | -30.2 M | -10.3 M | -49.3 M | -25.6 M | -30 M | 64.7 M | 390 K | 29.4 M | 6.22 M | -4.11 M | -7.66 M | -10.2 M |
Revenue |
419 M | 349 M | 321 M | 268 M | 242 M | 248 M | 299 M | 359 M | 321 M | 222 M | 187 M | 118 M | 59.2 M | 27.1 M | 7.8 M |
Cost of Revenue |
73 M | 60.1 M | 54.6 M | 48.3 M | 39.6 M | 39.3 M | 43.1 M | 36.4 M | 35.2 M | 30.9 M | - | - | - | - | - |
Gross Profit |
346 M | 289 M | 267 M | 220 M | 202 M | 209 M | 256 M | 323 M | 286 M | 192 M | 167 M | 106 M | 49.9 M | 21.9 M | 4.6 M |
Operating Income |
63.9 M | 58.9 M | 37.1 M | -14.7 M | -7.05 M | -45.4 M | -21.2 M | -3.92 M | 46.2 M | 884 K | 24.4 M | 7.1 M | -2.64 M | -5.36 M | -9.76 M |
Interest Expense |
-558 K | -565 K | -26 K | -4 K | -23 K | -3 K | 283 K | - | - | 339 K | 86 K | 48 K | 45.2 K | 593 K | 433 K |
EBITDA |
78.8 M | 64.9 M | 40.5 M | -11.4 M | -2.69 M | -39.6 M | -13.6 M | 2.99 M | 50.9 M | 6.35 M | 27.1 M | 9.22 M | -947 K | -3.51 M | -8.01 M |
Operating Expenses |
- | - | - | - | - | - | 277 M | 327 M | 240 M | 194 M | 143 M | 98.5 M | 52.1 M | 23.9 M | 14.4 M |
General and Administrative Expenses |
56.5 M | 49.5 M | 49.3 M | 57.4 M | 195 M | 181 M | 194 M | 253 M | 216 M | 170 M | 133 M | 90.5 M | 46.2 M | 19.6 M | 11.8 M |
All numbers in USD currency
Quarterly Income Statement MiMedx Group
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
148 M | 147 M | 147 M | 147 M | 147 M | 146 M | 146 M | 116 M | 116 M | 114 M | 114 M | 113 M | 113 M | 112 M | 112 M | 111 M | 110 M | 109 M | 111 M | 108 M | 108 M | 108 M | 111 M | 107 M | 107 M | 106 M | 109 M | 106 M | 106 M | 105 M | 109 M | 107 M | 107 M | 106 M | 110 M | 106 M | 106 M | 106 M | 107 M | 107 M | 106 M | 106 M | 108 M | 106 M | 106 M | 105 M | 104 M | 96.9 M | 96 M | 93.1 M | 88.4 M | 84.5 M | 80 M | 74.9 M | 74.3 M | 73.8 M | 71.8 M | 74.3 M |
Net Income |
9.62 M | 7.02 M | - | 8.1 M | 17.6 M | 9.26 M | - | 8.53 M | 1.2 M | -4.98 M | - | -8.43 M | -10.9 M | -10.5 M | - | -2.34 M | -1.78 M | -8.38 M | -16.6 M | -19.4 M | -8.47 M | -4.82 M | -7.48 M | 12.4 M | -17.2 M | -13.3 M | -36.2 M | -178 K | 1.8 M | 4.62 M | 4.28 M | 44.1 M | 10.4 M | 6 M | 5.48 M | 3.32 M | 1.98 M | 1.2 M | 13.4 M | 6.55 M | 5.43 M | 4.09 M | 3.83 M | 3.7 M | -390 K | -922 K | -1.43 M | -307 K | -757 K | -1.62 M | -1.6 M | -4.22 M | -744 K | -1.09 M | -2.58 M | -1.77 M | -2.5 M | -3.35 M |
Revenue |
98.6 M | 88.2 M | - | 84.1 M | 87.2 M | 84.7 M | - | 81.7 M | 81.3 M | 71.7 M | - | 67.7 M | 66.9 M | 58.9 M | - | 63.1 M | 68.2 M | 60 M | 68.5 M | 64.3 M | 53.6 M | 61.7 M | 76.4 M | 88.9 M | 67.4 M | 66.6 M | 92.6 M | 87 M | 95.4 M | 84.1 M | 87.9 M | 84 M | 80.5 M | 68.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
18.7 M | 16.6 M | - | 15.3 M | 14.9 M | 13 M | - | 14.8 M | 13.6 M | 12.4 M | - | 12.2 M | 11.8 M | 9.94 M | - | 10.1 M | 12.8 M | 9.64 M | - | 10.3 M | 8.2 M | 10 M | - | 13.2 M | 9.75 M | 7.42 M | - | 7.36 M | 9.27 M | 9.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
79.9 M | 71.6 M | - | 68.7 M | 72.4 M | 71.7 M | - | 66.9 M | 67.7 M | 59.3 M | - | 55.5 M | 55.1 M | 49 M | - | 52.9 M | 55.4 M | 50.3 M | 57.7 M | 54 M | 45.4 M | 51.7 M | 63.7 M | 75.7 M | 57.7 M | 59.1 M | 82.2 M | 79.6 M | 86.1 M | 74.8 M | 78.5 M | 74.7 M | 72 M | 60.8 M | 60.8 M | 56.4 M | 49.9 M | 45.4 M | 46.8 M | 44 M | 40.6 M | 35.6 M | 36 M | 30.2 M | 22.8 M | 16.6 M | 14.9 M | 14 M | 11.3 M | 9.65 M | 8.82 M | 6.53 M | 3.77 M | 2.75 M | 1.72 M | 1.27 M | 1.08 M | 333 K |
Operating Income |
12.4 M | 8.25 M | - | 11.2 M | 23.4 M | 13.2 M | - | 11.1 M | 10.8 M | -340 K | - | -7.1 M | -9.64 M | -9.3 M | - | -1.08 M | -410 K | -6.85 M | - | -9.71 M | -5.86 M | -13.7 M | - | 14.2 M | -17.1 M | -13.4 M | - | 373 K | 1.68 M | 2.97 M | - | 8.84 M | 7.21 M | 6.18 M | - | 4.7 M | 3.56 M | 1.47 M | - | 6.71 M | 5.65 M | 4.25 M | - | 3.73 M | -392 K | -891 K | - | -256 K | -744 K | -227 K | - | -3.63 M | -118 K | -631 K | - | -1.65 M | -2.42 M | -3.26 M |
Interest Expense |
-101 K | -145 K | - | -21 K | -237 K | -99 K | - | -11 K | -32 K | 2 K | - | - | - | -1.13 M | - | - | -3 K | - | - | 1 K | -9 K | 6 K | - | 127 K | 174 K | -29 K | - | - | - | - | - | -43 K | -149 K | -145 K | - | -87 K | -111 K | -56 K | - | -5 K | 1 K | 14 K | - | 9.13 K | 8.43 K | 21 K | - | 4.53 K | 13.2 K | 14.8 K | - | 146 K | 154 K | 152 K | - | 32.7 K | 26.5 K | 91.2 K |
EBITDA |
12.9 M | 8.81 M | - | 11.4 M | 24 M | 13.8 M | - | 11.3 M | 11 M | 374 K | - | -6.27 M | -8.78 M | -8.44 M | - | -152 K | 896 K | -5.69 M | - | -8.14 M | -4.43 M | -12.2 M | - | 15.8 M | -15.5 M | -11.7 M | - | 1.77 M | 2.98 M | 4.19 M | - | 9.86 M | 8.33 M | 7.13 M | - | 5.54 M | 4.38 M | 2.2 M | - | 7.18 M | 6.07 M | 4.6 M | - | 4.04 M | -104 K | -628 K | - | -70.9 K | -605 K | -128 K | - | -3.28 M | 114 K | -521 K | - | -1.32 M | -2.18 M | -3.14 M |
General and Administrative Expenses |
16.3 M | 13.1 M | - | 53.5 M | 13.7 M | 10.7 M | - | 52.6 M | 52 M | 52.2 M | - | 53.5 M | 55.8 M | 49.6 M | - | 46.3 M | 53.6 M | 45.4 M | - | 48 M | 37.3 M | 46.9 M | - | 51.3 M | 50.6 M | 50.9 M | - | 58.7 M | 67.6 M | 65.9 M | - | 60.2 M | 55.3 M | 53 M | - | 48.2 M | 42.8 M | 40.6 M | - | 34.9 M | 32.7 M | 29.3 M | - | 24.2 M | 21.2 M | 15.9 M | - | 12.7 M | 10.9 M | 8.37 M | - | 5.76 M | 3.05 M | 2.64 M | - | 2.36 M | 2.71 M | 2.63 M |
All numbers in USD currency
Main types of financial statements MiMedx Group MDXGFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting MiMedx Group plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Inogen
INGN
|
$ 6.32 | -2.02 % | $ 168 M | ||
|
IRadimed Corporation
IRMD
|
$ 99.89 | 0.69 % | $ 1.27 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.35 | -0.04 % | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
LivaNova PLC
LIVN
|
$ 63.27 | 0.05 % | $ 3.45 B | ||
|
LENSAR
LNSR
|
$ 5.71 | -5.93 % | $ 65.8 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | ||
|
AxoGen
AXGN
|
$ 32.42 | 2.11 % | $ 1.49 B | ||
|
CONMED Corporation
CNMD
|
$ 36.72 | 0.25 % | $ 1.14 B | ||
|
Medtronic PLC
MDT
|
$ 86.65 | -0.64 % | $ 111 B | ||
|
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
$ 24.67 | 0.73 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
- | - | $ 462 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.72 | 6.7 % | $ 39.2 M | ||
|
Aethlon Medical
AEMD
|
$ 2.15 | -6.52 % | $ 3.36 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Orthofix Medical
OFIX
|
$ 11.77 | -0.84 % | $ 466 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 11.48 | 10.66 % | $ 1.55 B | ||
|
Myomo
MYO
|
$ 0.69 | -2.17 % | $ 28.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 2.33 | -4.71 % | $ 137 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.85 | 3.08 % | $ 144 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 15.84 | -3.83 % | $ 372 M | ||
|
Penumbra
PEN
|
$ 334.58 | -0.3 % | $ 13 B | ||
|
Outset Medical
OM
|
$ 3.49 | -3.6 % | $ 53.1 K | ||
|
Inspire Medical Systems
INSP
|
$ 51.53 | -1.3 % | $ 1.51 B | ||
|
Insulet Corporation
PODD
|
$ 225.21 | -0.82 % | $ 15.8 B | ||
|
Profound Medical Corp.
PROF
|
$ 5.1 | -5.56 % | $ 180 M | ||
|
Pulmonx Corporation
LUNG
|
$ 1.33 | -4.68 % | $ 54.1 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.68 | -6.73 % | $ 157 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
InspireMD
NSPR
|
$ 1.8 | 4.05 % | $ 116 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M |